Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Farid Adrienne, the Chief Operations Officer of Century Therapeutics , Inc. (NASDAQ:IPSC), recently sold shares of the company. According to a recent SEC filing, Adrienne sold 1,054 shares of common stock on February 3, 2025, at a price of $0.78 per share, totaling $822. The transaction occurred near the stock’s 52-week low of $0.75, with the shares down over 80% in the past year. InvestingPro analysis suggests the stock is currently undervalued. This transaction was carried out to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the filing. Following this sale, Adrienne retains ownership of 134,076 shares of Century Therapeutics. The micro-cap company, valued at approximately $68 million, carries a "Weak" financial health score according to InvestingPro metrics, though analysts maintain optimistic price targets ranging from $4 to $12.
In other recent news, Century Therapeutics has launched a Phase 1/2 trial, named CARAMEL, for its investigational cell therapy CNTY-101 in partnership with Friedrich-Alexander University Erlangen-Nürnberg. The trial aims to assess the therapy’s safety and efficacy in treating B-cell mediated autoimmune diseases. Concurrently, Century Therapeutics has also been advancing its Phase 1 CALiPSO-1 study of CNTY-101 in various autoimmune diseases, with Piper Sandler maintaining an Overweight rating for the company despite a significant price target reduction.
In a notable development, Bristol-Myers Squibb (NYSE:BMY) has decided to end its collaboration with Century Therapeutics on the development of CNTY-104 for acute myeloid leukemia and CNTY-106 for multiple myeloma. Despite this setback, Century Therapeutics remains optimistic about the scientific advancements made in these programs and plans to continue exploring opportunities in these areas.
Meanwhile, Clear Street has initiated coverage on Century Therapeutics with a Buy rating and a price target of $9.00, highlighting the potential of the company’s induced pluripotent stem cell platform and Allo-Evasion technology. These recent developments underscore the dynamic nature of Century Therapeutics’ operations in the cell therapy domain.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.